In 2013 some amino acid enterprises reported.

OA_show ('533');aXWmanufacturers 2013 mid-year report enterprise status, reason analysisXijie first-half sales revenue (including South Korea sales) 5201.8 billion won, up 8.09 percent YoY;Bioandaline sales revenue was 953.4 billion won, up 0.89% YoY, while total profits were 302.4 billion won, down 14.91% YoYOn the biological front, the increase in lysine production from the new plant in Shenyang offset the decline in lysine unit price, but profits continued to decline, mainly due to the continued low price of lysineDacheng Biochemicals' first-half sales revenue was HK$505,087 million, a decrease of 16.45% over the same period, sales costs were HK$518,307 million, an increase of 1.58% over the same period, and gross profit was HK$214.2 million, a decrease of 1.25 times over the same period last yearThe average unit price of lysine, the main product, has been declining since the fourth quarter of 2012Financial reasons (1) The average selling price and demand of products, in particular the impact of the sale of lysine products, were affected by avian influenza; (2) the decline in sales prices resulted in a impairment loss on inventories of biochemical alcohol products; (3) the adverse market conditions of biochemical alcohol products resulted in impairment losses on the Group's production facilities; and (4) the average cost of corn grain increased by about 11% to HK$2,509/tonne over the same period last yearMeihua Group achieved operating income of RMB3,922 million in the first half of the year, up 3.54% YoY, operating costs of RMB3.145 billion, up 5.34% YoY, with total profit s279 million, and net profit attributable to shareholders of listed companies of RMB220 million, a decrease of 21.75% compared with the same period last yearAs the second largest main business amino acid industry operating income of 1.103 billion yuan, up 12.94 percent YoY; operating costs of 900 million yuan, up 21.04 percent YoY; gross margin of 18.41 percent, down 5.52 percentage points from the same period last yearThe main reason for the increase in amino acid revenue is the increase in production at the base in Xinjiang, but with the fierce competition associated with the expansion of production capacity in the amino acid industry and the impact of avian influenza on the feed amino acid industry, the gross margin decreasesChina Starch First Half Turnover of RMB153,617 million, down 1.80% YoY; sales cost of RMB136,547 million, down 1.59% YoY; gross profit of RMB17.07 million, decrease of 3.43% YoY; operating profit of RMB99.04 million, down 17.22% YoY; net profit decreased by 14.06% YoYLysine and Fertilizer are the Group's second largest sub-business, accounting for about 16.8% of the Group's total turnoverLysine and fertilizer turnover was RMB257.69 million, down 10.78% YoY, while gross margin was RMB73.94 million, down 26.98% YoY, and gross margin was 28.70%, down 6.4 percentage points YoYSales of lysine products increased from 25,979 tonnes to 30,096 tonnes, but the gross margin and gross margin of the relevant business segment decreased, mainly due to lower prices of lysine productsCofco Realized First Half Year's operating income of RMB375,821.38 million, down 3.08% YoY; operating costs of RMB343,662.22 million, down 2.60% YoY; and net profit attributable to the parent company was RMB4,285.82 million, down 48.27% YoYOperating income of the main products amino acids and their by-products and other items was RMB858,918,750.24, up 0.95% YoY; operating costs were RMB761,690,243.84, up 21.83% YoY; and gross margin was 11.32%, down 6.74 percentage points YoY The decline in corporate income was due to the decline in the gross profit margin of citric acid and lysine compared with the same period last year, the impact of falling prices of highly competitive products and the rise in raw material prices ,000 Yufeng Group's first-half sales revenue was RMB574,155 million, up 3.64% YoY; sales cost was RMB481,531 million, up 2.13% YoY; sales margin was RMB92,623 million, up 12.30% YoY; gross margin was 16.10%, up 1.2% YoY;Susine's earnings amounted to ABOUT RMB131.6 million, up 72.41 percent year-on-year, accounting for 2.29 percent of total sales revenue In the first half of the year, 13,856 tons were sold, up 79.0% YoY (2012 sales of 7,742 tonnes) Susine is a relatively new product of the Group, with an annual production capacity of about 40,000 tons The Group continues to develop susine and lysine products In addition, the high-grade amino acids (including proline, leucine, ialyanine and glutamine) business for the Group's new growth momentum, the estimated annual production capacity of high-grade amino acids 3,000 tons Sublimation Byk Achieved operating income of RMB81,962.03 million in the first half of the year, a decrease of 0.2% YoY; operating costs of RMB717,999.67 million, up 1.40% YoY; operating profit of RMB2,373.02 million, down 27.98% YoY; net profit attributable to shareholders of listed companies decreased by 24.11% YoY Non-colored inline production, but not for the main business The company's annual output of 20,000 tons of 10% L-tryptophan premix and 500 tons of L-tryptophan project has been completed 85%, some have been put into use, part is still under construction Downstream says the company also supplies 20% of its products Lu Anti-Pharmaceutical company's sales revenue in the first half of the year was RMB117,324 million, down 3.73% YoY; operating expenses were RMB101,056 million, down 6.60% YoY; net profit was RMB23.98 million, down RMB47.48 million YoY, an increase of 66.44%, and the turnaround work was the first to bear fruit Among them, wholly-owned subsidiary Shandong Lu Anti-BioManufacturing Co., Ltd., the main tryptophan manufacturing, etc., in the reporting period to achieve operating income of 47.55 million yuan, net profit of 21.45 million yuan Non-colored inline production, but not for the main business The downward adjustment in tryptophan prices comes from the impact of rising corn costs, and so on Xinghu Technology Company realized operating income of RMB46,660.99 million in the first half of the year, up 9.96% YoY; operating cost was RMB44,901.54 million, up 4.75% YoY; net profit attributable to parent company -5,21 0.82 million yuan, a decrease of 3.61% over the same period last year, and net profit attributable to shareholders of listed companies, net profit attributable to shareholders of listed companies, net income of 14,193.89 million yuan (previous year -12,773.12 million yuan) Among them, feed additive operating income was RMB33,641.2 million, a decrease of 32.62% YoY, and operating costs decreased by RMB5.4242 million, a decrease of 46.57% YoY, with gross margin of 5.3%, a decrease of 27.5 percentage points The main reason for the decrease in feed additive revenue is due to the decrease in the income of Susine, the current production line of Susine due to temporary shutdown idle, after the completion of the necessary transformation will resume production, the time is not clear The company said that there is a small amount of lysine production, low content mainly OA_show ('533'); aXW manufacturers in 2013 mid-year report enterprise status, reason analysis Xijie first-half sales revenue (including Sales in South Korea) 5201.8 billion won, up 8.09 percent YoY;Bioandaline sales revenue was 953.4 billion won, up 0.89% YoY, while total profits were 302.4 billion won, down 14.91% YoY On the biological front, the increase in lysine production from the new plant in Shenyang offset the decline in lysine unit price, but profits continued to decline, mainly due to the continued low price of lysine Dacheng Biochemicals' first-half sales revenue was HK$505,087 million, a decrease of 16.45% over the same period, sales costs were HK$518,307 million, an increase of 1.58% over the same period, and gross profit was HK$214.2 million, a decrease of 1.25 times over the same period last year The average unit price of lysine, the main product, has been declining since the fourth quarter of 2012 Financial reasons (1) The average selling price and demand of products, in particular the impact of the sale of lysine products, were affected by avian influenza; (2) the decline in sales prices resulted in a impairment loss on inventories of biochemical alcohol products; (3) the adverse market conditions of biochemical alcohol products resulted in impairment losses on the Group's production facilities; and (4) the average cost of corn grain increased by about 11% to HK$2,509/tonne over the same period last year Meihua Group achieved operating income of RMB3,922 million in the first half of the year, up 3.54% YoY, operating costs of RMB3.145 billion, up 5.34% YoY, with total profit s279 million, and net profit attributable to shareholders of listed companies of RMB220 million, a decrease of 21.75% compared with the same period last year As the second largest main business amino acid industry operating income of 1.103 billion yuan, up 12.94 percent YoY; operating costs of 900 million yuan, up 21.04 percent YoY; gross margin of 18.41 percent, down 5.52 percentage points from the same period last year The main reason for the increase in amino acid revenue is the increase in production at the base in Xinjiang, but with the fierce competition associated with the expansion of production capacity in the amino acid industry and the impact of avian influenza on the feed amino acid industry, the gross margin decreases China Starch First Half Turnover of RMB153,617 million, down 1.80% YoY; sales cost of RMB136,547 million, down 1.59% YoY; gross profit of RMB17.07 million, decrease of 3.43% YoY; operating profit of RMB99.04 million, down 17.22% YoY; net profit decreased by 14.06% YoY Lysine and Fertilizer are the Group's second largest sub-business, accounting for about 16.8% of the Group's total turnover Lysine and fertilizer turnover was RMB257.69 million, down 10.78% YoY, while gross margin was RMB73.94 million, down 26.98% YoY, and gross margin was 28.70%, down 6.4 percentage points YoY Sales of lysine products increased from 25,979 tonnes to 30,096 tonnes, but the gross margin and gross margin of the relevant business segment decreased, mainly due to lower prices of lysine products Cofco Realized First Half Year's operating income of RMB375,821.38 million, down 3.08% YoY; operating costs of RMB343,662.22 million, down 2.60% YoY; and net profit attributable to the parent company was RMB4,285.82 million, down 48.27% YoY Operating income of the main products amino acids and their by-products and other items was RMB858,918,750.24, up 0.95% YoY; operating costs were RMB761,690,243.84, up 21.83% YoY; and gross margin was 11.32%, down 6.74 percentage points YoY The decline in corporate income was due to the decline in the gross profit margin of citric acid and lysine compared with the same period last year, the impact of falling prices of highly competitive products and the rise in raw material prices ,000 Yufeng Group's first-half sales revenue was RMB574,155 million, up 3.64% YoY; sales cost was RMB481,531 million, up 2.13% YoY; sales margin was RMB92,623 million, up 12.30% YoY; gross margin was 16.10%, up 1.2% YoY;Susine's earnings amounted to ABOUT RMB131.6 million, up 72.41 percent year-on-year, accounting for 2.29 percent of total sales revenue In the first half of the year, 13,856 tons were sold, up 79.0% YoY (2012 sales of 7,742 tonnes) Susine is a relatively new product of the Group, with an annual production capacity of about 40,000 tons The Group continues to develop susine and lysine products In addition, the high-grade amino acids (including proline, leucine, ialyanine and glutamine) business for the Group's new growth momentum, the estimated annual production capacity of high-grade amino acids 3,000 tons Sublimation Byk Achieved operating income of RMB81,962.03 million in the first half of the year, a decrease of 0.2% YoY; operating costs of RMB717,999.67 million, up 1.40% YoY; operating profit of RMB2,373.02 million, down 27.98% YoY; net profit attributable to shareholders of listed companies decreased by 24.11% YoY Non-colored inline production, but not for the main business The company's annual output of 20,000 tons of 10% L-tryptophan premix and 500 tons of L-tryptophan project has been completed 85%, some have been put into use, part is still under construction Downstream says the company also supplies 20% of its products Lu Anti-Pharmaceutical company's sales revenue in the first half of the year was RMB117,324 million, down 3.73% YoY; operating expenses were RMB101,056 million, down 6.60% YoY; net profit was RMB23.98 million, down RMB47.48 million YoY, an increase of 66.44%, and the turnaround work was the first to bear fruit Among them, wholly-owned subsidiary Shandong Lu Anti-BioManufacturing Co., Ltd., the main tryptophan manufacturing, etc., in the reporting period to achieve operating income of 47.55 million yuan, net profit of 21.45 million yuan Non-colored inline production, but not for the main business The downward adjustment in tryptophan prices comes from the impact of rising corn costs, and so on Xinghu Technology Company realized operating income of RMB46,660.99 million in the first half of the year, up 9.96% YoY; operating cost was RMB44,901.54 million, up 4.75% YoY; net profit attributable to parent company -5,21 0.82 million yuan, a decrease of 3.61% over the same period last year, and net profit attributable to shareholders of listed companies, net profit attributable to shareholders of listed companies, net income of 14,193.89 million yuan (previous year -12,773.12 million yuan) Among them, feed additive operating income was RMB33,641.2 million, a decrease of 32.62% YoY, and operating costs decreased by RMB5.4242 million, a decrease of 46.57% YoY, with gross margin of 5.3%, a decrease of 27.5 percentage points The main reason for the decrease in feed additive revenue is due to the decrease in the income of Susine, the current production line of Susine due to temporary shutdown idle, after the completion of the necessary transformation will resume production, the time is not clear The company said that there is a small amount of lysine production, low content mainly .